American Association for Cancer Research
21598290cd191390-sup-233132_2_supp_6265632_q9x2x2.pdf (590.6 kB)

Supplemental Figure 3 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Download (590.6 kB)
journal contribution
posted on 2023-04-03, 22:23 authored by Seth A. Wander, Ofir Cohen, Xueqian Gong, Gabriela N. Johnson, Jorge E. Buendia-Buendia, Maxwell R. Lloyd, Dewey Kim, Flora Luo, Pingping Mao, Karla Helvie, Kailey J. Kowalski, Utthara Nayar, Adrienne G. Waks, Stephen H. Parsons, Ricardo Martinez, Lacey M. Litchfield, Xiang S. Ye, Chunping Yu, Valerie M. Jansen, John R. Stille, Patricia S. Smith, Gerard J. Oakley, Quincy S. Chu, Gerald Batist, Melissa E. Hughes, Jill D. Kremer, Levi A. Garraway, Eric P. Winer, Sara M. Tolaney, Nancy U. Lin, Sean G. Buchanan, Nikhil Wagle

Figure S3


Department of Defense

Landon Foundation



Susan G. Komen



Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor–positive (HR+) breast cancer have not been clearly defined. Whole-exome sequencing of 59 tumors with CDK4/6i exposure revealed multiple candidate resistance mechanisms including RB1 loss, activating alterations in AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2, and loss of estrogen receptor expression. In vitro experiments confirmed that these alterations conferred CDK4/6i resistance. Cancer cells cultured to resistance with CDK4/6i also acquired RB1, KRAS, AURKA, or CCNE2 alterations, which conferred sensitivity to AURKA, ERK, or CHEK1 inhibition. Three of these activating alterations—in AKT1, RAS, and AURKA—have not, to our knowledge, been previously demonstrated as mechanisms of resistance to CDK4/6i in breast cancer preclinically or in patient samples. Together, these eight mechanisms were present in 66% of resistant tumors profiled and may define therapeutic opportunities in patients. We identified eight distinct mechanisms of resistance to CDK4/6i present in 66% of resistant tumors profiled. Most of these have a therapeutic strategy to overcome or prevent resistance in these tumors. Taken together, these findings have critical implications related to the potential utility of precision-based approaches to overcome resistance in many patients with HR+ metastatic breast cancer.This article is highlighted in the In This Issue feature, p. 1079

Usage metrics

    Cancer Discovery



    Ref. manager